217 W. MAIN STREET, SOMERVILLE, NJ
ZyVersa Therapeutics Enters $1 Million Securities Purchase Agreement
Director Resignation - Robert G. Finizio Steps Down from Board
Reports Third Quarter 2025 Financial Results
Pablo Guzman Resigns as Chief Medical Officer of ZyVersa Therapeutics
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
News
News, Securities Holder Rights or Indentures, Material Contracts
FY 2025
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload